Skip to main content
For Commercial Teams

Unparalleled reach across 15% of the U.S. oncology care delivery network

OncoLens turns EMR and lab activity, inpatient and outpatient alike, into signals that are paired with direct HCP and cancer center engagement.

Talk with a Life Sciences expert See network coverage
A continuous loop. Signal (biomarkers, progression, treatment) flows from 225+ community cancer centers to the engagement engine. The return (alerts, tumor boards, education) flows back to the cancer centers. OncoLens sits at the center.

How OncoLens helps

Three steps, run as one continuous motion: detect the signal, educate the physician, engage the cancer center.

Detect

OncoLens detects EMR-based oncology signals for commercial teams

  • In-house lab and NGS vendor biomarker results
  • Treatment-based indicators
  • Progression indicators
Educate

OncoLens delivers omnichannel HCP education at the decision point

  • Sequenced across pre-launch, launch, and post-launch
  • Matched to the HCP’s stage of awareness
  • Delivered across the channels physicians already work in
Engage

OncoLens engages cancer centers directly, without added headcount

  • Direct partnership with HCPs and cancer centers
  • Eligible patients identified and flagged to care teams
  • Improved quality and workflows
  • Expanded sales team reach without added headcount

Sequenced across the launch lifecycle

EMR-based signals decide which centers and physicians to prioritize at each stage, so outreach tracks where the patient population actually is.

  1. Pre-launch

    Awareness building

    HCP alerts in the decision workflow

  2. Launch

    Adoption support

    Center prioritization by signal

  3. Post-launch

    Reinforcement

    Omnichannel outreach and tumor boards

Methodology

Four ways OncoLens reaches physicians and cancer centers inside the decision-making workflow.

1

Alerts to HCPs within the decision-making workflow

2

Quality improvement initiatives

3

Educational webinars based on decision-making patterns

4

Tumor boards and e-consults with KOLs

OncoLens’ data isn’t limited to just what was triggered by biomarker testing or available in the outpatient settings. The OncoLens longitudinal view stands out.

County-level map showing where patients under care in the OncoLens network are concentrated across the United States, with Alaska and Hawaii shown as insets
Where patients under care are concentrated
225+U.S.-based cancer center locations
6,000,000+patients under care
90%community-based
88%AI-extracted insights

Frequently asked questions

How does OncoLens identify commercial opportunities before they show up in claims data?

OncoLens monitors EMR data in real time to surface biomarker results as they’re generated, whether identified through a cancer center’s in-house lab or an external NGS vendor, along with treatment- and progression-based indicators that signal a patient is approaching a treatment decision. Because this happens inside the clinical workflow rather than after claims are billed, commercial teams can engage weeks earlier than data sources limited to claims or outpatient pharmacy fills.

Why does inpatient and outpatient coverage matter for a commercial strategy?

Many oncology data sources capture only outpatient activity, which misses a meaningful share of testing, diagnosis, and treatment decisions that happen in the inpatient setting. OncoLens spans both settings and connects them to a patient’s longitudinal history, so commercial teams get a complete view of where a patient is in their care journey rather than a fragmented outpatient-only snapshot.

How does OncoLens support HCP engagement beyond identifying a testing event?

Signal detection is only the starting point. OncoLens pairs it with direct engagement, including participation in tumor boards and e-consults and data-driven omnichannel outreach to the HCPs and cancer centers managing that patient. This lets commercial teams act on a signal with a coordinated engagement motion rather than a one-off notification.

How does OncoLens help commercial teams sequence engagement across a product launch?

OncoLens structures HCP and cancer-center engagement across pre-launch, launch, and post-launch phases, using EMR-based signals to determine which cancer centers and physicians to prioritize at each stage. This keeps outreach aligned to where the patient population actually is in their treatment journey, rather than a single generic campaign spanning the whole lifecycle.

What does “reach” mean in the context of OncoLens’s network?

OncoLens’s network spans 15% of the U.S. oncology care delivery network across both outpatient and inpatient settings, giving commercial teams reach into a broad and clinically diverse set of cancer centers rather than a narrow slice defined by a single data type or care setting. That breadth, combined with real-time actionability, is what allows commercial teams to engage while a treatment decision is still being made, not after it’s already been finalized.

Explore other audiences

OncoLens supports teams across the life sciences organization.

Audience

RWE and HEOR

Data captured at the point of clinical decision-making, not just claims.

 Audience

Clinical Development

Reduce uncertainty from feasibility through enrollment.

 Audience

CROs and Biobanks

Scale at your fingertips through engaging a singular, diverse network.

 Audience

Market Access and Data Insights

Where real-world care diverges from guidelines.
Get in touch

Engage while the decision is still being made

Share which signals matter to your brand, and OncoLens will show you how fast it can get them in front of the right physician.